伊格列净与吡格列酮对2型糖尿病合并非酒精性脂肪性肝病患者疗效比较:一项随机、24周、开放标签、活性对照试验
该开放标签随机对照试验将66例2型糖尿病合并NAFLD患者随机分为伊格列净50 mg组(n=32)或吡格列酮15-30 mg组(n=34),每日口服一次。第24周时两组肝脏与脾脏CT衰减比(L/S比)平均增幅分别为0.22和0.21(P=0.90),转氨酶、HbA1c及空腹血糖降幅相似,但体重和内脏脂肪面积仅在伊格列净组显著下降。
要点
- 伊格列净50 mg与吡格列酮15-30 mg对NAFLD和血糖控制的改善效果相当。
- 第24周L/S比增幅:伊格列净组0.22 vs 吡格列酮组0.21(P=0.90)。
- 体重和内脏脂肪面积仅在伊格列净组较吡格列酮组显著降低(P<0.0001和P=0.0013)。
核心结论
- 与吡格列酮相比,伊格列净在治疗2型糖尿病合并NAFLD患者时对NAFLD和血糖控制具有同等有益效果,且显著降低体重和腹部脂肪面积。
研究设计与样本
- 开放标签、随机、活性对照试验,纳入66例2型糖尿病合并NAFLD患者,随机分配至伊格列净50 mg组(n=32)或吡格列酮15-30 mg组(n=34),每日口服一次。
- 主要结局为第24周时CT肝脏与脾脏衰减比(L/S比)较基线的变化。
主要发现
- 第24周L/S比平均±标准差增幅:伊格列净组0.22(从0.80±0.24升至1.00±0.18)vs 吡格列酮组0.21(从0.78±0.26升至0.98±0.16),P=0.90。
- 两组血清天冬氨酸氨基转移酶、丙氨酸氨基转移酶、HbA1c和空腹血糖降幅相似。
- 体重和内脏脂肪面积仅在伊格列净组较吡格列酮组显著降低(P<0.0001和P=0.0013)。
- 两组均无严重不良事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the efficacy of ipragliflozin versus pioglitazone in patients with type 2 diabetes complicated by nonalcoholic fatty liver disease (NAFLD). RESEARCH DESIGN AND METHODS: In this open-label, randomized, active-controlled trial, we randomly assigned 66 patients with type 2 diabetes and NAFLD to receive ipragliflozin 50 mg (n = 32) or pioglitazone 15-30 mg (n = 34) orally once daily. The primary outcome was a change from baseline in the liver-to-spleen attenuation ratio (L/S ratio) on computed tomography at week 24. RESULTS: At week 24, the mean ± SD L/S ratio had increased by 0.22 (from 0.80 ± 0.24 to 1.00 ± 0.18) in the ipragliflozin group and 0.21 (from 0.78 ± 0.26 to 0.98 ± 0.16) in the pioglitazone group (P = 0.90). Serum aspartate and alanine aminotransferase levels, HbA1c, and fasting plasma glucose were similarly reduced in the two treatment groups. Nevertheless, body weight and visceral fat area showed significant reductions only in the ipragliflozin group compared with the pioglitazone group (P < 0.0001 and P = 0.0013, respectively). There were no serious adverse events in either group. CONCLUSIONS: Compared with pioglitazone, ipragliflozin exerts equally beneficial effects on NAFLD and glycemic control during the treatment of patients with type 2 diabetes complicated by NAFLD. Furthermore, ipragliflozin significantly reduced body weight and abdominal fat area.
引用
- Ito D, Shimizu S, Inoue K, et al. Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial. Diabetes Care. 2017. PMID: 28751548. doi:10.2337/dc17-0518
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。